PEYNIER, France, July 12, 2023 /PRNewswire/ — Gustave Roussy and THERYQ announce a strategic and structuring partnership to implement and evaluate FLASH technology in radiotherapy. The French medical technology company THERYQ, specialized in particle accelerators and radiotherapy systems, has provided Gustave Roussy’s Department of Radiotherapy with the first FLASH clinical radiotherapy machine in France for the treatment of superficial tumors.
The collaboration between Gustave Roussy, the leading cancer center in Europe and the third in the world, and THERYQ, a French company specializing in the manufacture of FLASH radiotherapy systems, represents a breakthrough in cancer treatment in France with the arrival of the first FLASHKNiFE® machine .
FLASHKNiFE® technology is a new radiation therapy process that uses electrons. The FLASH radiation therapy system provides a very high dose rate, allowing professionals to treat patients in milliseconds. Several preclinical studies have shown that this technique can save healthy tissue while effectively destroying tumor cells. In addition, the very short irradiation time eliminates any movement of the organ or tumor, ensuring more precise and controlled targeting.
Thanks to this important collaboration, Gustave Roussy will be the first center in France to use THERYQ’s FLASH radiotherapy machine. Before its widespread use, a clinical study will be conducted to assess the efficacy of FLASH radiotherapy in patients with skin cancer. The results of this study could have a significant impact in the treatment of skin cancer, thus paving the way for new therapeutic advances, including in the treatment of all solid tumors.
Professor Eric Deutsch, Head of Gustave Roussy’s Department of Radiotherapy, said: “The introduction of this system will allow FLASH radiotherapy, a significant evolution of current methods, to undergo extensive clinical testing. Reducing the number of sessions , along with the possibility of minimizing radiation-induced side effects, will lead to more tolerable and effective treatments. We are fully involved and motivated by this project, which holds out the hope of significantly improving therapeutic management.”
Ludovic Le Meunier, CEO of THERYQ, added: “We are delighted to work with Gustave Roussy, a pioneer in cancer research and treatment, to introduce FLASH radiotherapy in France. This collaboration marks a key milestone in our goal of delivering solutions advanced treatments to patients. FLASH radiotherapy has enormous potential to improve the treatment of patients with skin cancer and we look forward to the results of this study.”
Gustave Roussy and THERYQ commit to continue their joint effort to develop innovative treatments for the benefit of patients, leading to more effective and tolerable radiotherapy thanks to this promising technology.
Acerca by Gustave Roussy:
Gustave Roussy, the first in Europe and the third in the world, is a global center of expertise entirely dedicated to cancer patients. The Institute is one of the founding pillars of the Paris Saclay Cancer Cluster. A source of therapeutic innovation and diagnostic advances, the Institute receives nearly 50,000 patients each year and develops an integrated approach that combines research, care and teaching. Gustave Roussy offers expert care for rare cancers and complex tumors, treating all types of cancer at all stages of life. It offers its patients personalized management that combines innovation and a human-centred approach, taking into account care and the physical, psychological and social quality of life. With 4,100 employees in two centers, Villejuif and Chevilly-Larue, Gustave Roussy brings together the necessary experience for high-level cancer research, with a quarter of patients included in clinical trials.
More information about Gustave Roussy and the latest news from the Institute on www.gustaveroussy.fr, as well as on Twitter, Facebook, LinkedIn and Instagram.
About THERYQ:
THERYQ, a spin-off of PMB-ALCEN located in the South of France, is an innovative medical technology company specializing in particle accelerators and radiotherapy systems. The company possesses and contributes essential knowledge in project management, RD, industrialization and production. THERYQ is part of the Health branch of ALCEN Group.
Follow us on LinkedIn and visit our website www.theryq.com.
Contact: Fatine Slaouifslaoui@theryq.com 33 4 42 53 13 13
Photo – https://mma.prnewswire.com/media/2150677…Logo – https://mma.prnewswire.com/media/2150679…
View original content: https://www.prnewswire.com/news-releases/gustave-roussy-y-theryq–francia-recibe-la-primera-maquina-de-radioterapia-flash-para-tratar-pacientes-301875890.html
